• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by ZyVersa Therapeutics Inc.

    9/18/25 7:00:46 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZVSA alert in real time by email
    false 0001859007 0001859007 2025-09-14 2025-09-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported):   September 14, 2025

     

    ZYVERSA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41184   86-2685744

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    2200 N. Commerce Parkway, Suite 208, Weston, Florida   33326
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code:   (754) 231-1688

     

    Not Applicable

     

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   ZVSA   —(1)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

    (1) On September 14, 2025, the Nasdaq Stock Market notified ZyVersa Therapeutics, Inc. (the “Company”) of its plans to announce the delisting of the Company’s common stock and file a Form 25 with the Securities and Exchange Commission on or about September 18, 2025. The Company’s common stock is trading on the OTCQB® Venture Market under the symbol “ZVSA.”

     

     

     

     

     

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    On September 14, 2025, the Nasdaq Stock Market (“Nasdaq”) notified ZyVersa Therapeutics, Inc. (the “Company”) that, on September 18, 2025, it will announce the delisting of the Company’s common stock. The Company’s common stock was suspended from trading on The Nasdaq Capital Market on July 17, 2025, and has been trading on the OTCQB® Venture Market (the “OTCQB”) under the symbol “ZVSA” since July 28, 2025. Nasdaq will file a Form 25 with the Securities and Exchange Commission (the “SEC”) to complete the delisting in accordance with Rule 12d2-2 promulgated under the Securities Exchange Act of 1934, as amended. The delisting will become effective ten days after the Form 25 is filed. The Company’s common stock will continue trading on the OTCQB without disruption.

     

    As previously reported on the Company’s Current Report on Form 8-K filed with the SEC on July 16, 2025, the Company received written notice from the Nasdaq Hearings Panel (the “Panel”) on July 15, 2025, indicating that the Panel had determined to delist the Company’s securities from Nasdaq and that trading in the Company’s securities would be suspended at the open of trading on July 17, 2025, due to the Company’s failure to regain compliance with the minimum bid price requirements under Listing Rule 5550(a)(2).

     

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

     

    This Current Report on Form 8-K (“Form 8-K”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the timing of the delisting of the Company’s common stock. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks, uncertainties and other important factors, including those factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, in each case as filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 8-K. Any forward-looking statements speak only as of the date of this Form 8-K and are based on information available to the Company as of the date of this Form 8-K, and the Company assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: September 18, 2025 ZYVERSA THERAPEUTICS, INC.
       
      /s/ Stephen Glover
      Stephen Glover
      Chief Executive Officer

     

     

     

    Get the next $ZVSA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZVSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZVSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes

    Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke.Cardiovascular complications are a leading cause of disability and death in people with T2DM. People with T2DM are 2 to 4 times more likely to experience cardiovascular events than people without T2DM, and post-event outcomes are often worse. About half of all diabetes-related fatalities can be attributed to cardiovascular causes.The published data provide evidence that inflammasome-induced inflammation plays a central role in the development and progression of T2DM and its cardiovascular complic

    9/10/25 7:55:00 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

    KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with interim results expected ~Q4-2025. IND-enabling obesity preclinical study with Inflammasome ASC Inhibitor IC 100 in a diet-induced obesity (DIO) animal model planned to begin ~Q4-2025. Invited MJFF grant request submitted for funding Parkinson's disease animal model proof-of-concept studies; response expected Q3-2025. Raised approximately $2.05 million since the end of Q2-2025; $4.05 million year-to-date. WESTON, Fla., Aug. 13, 2025 (GLOBE NEWSWIR

    8/13/25 9:00:00 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress

    WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA, "ZyVersa")), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, has issued a mid-year Shareholder Letter to update investors on recent corporate developments and to highlight near-term value-building R&D milestones for second half of 2025. The full text of the letter follows. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Shareholders: Over my 40-year career, I've seen the full a

    7/21/25 7:55:00 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVSA
    SEC Filings

    View All

    SEC Form 8-K filed by ZyVersa Therapeutics Inc.

    8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

    9/18/25 7:00:46 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ZyVersa Therapeutics Inc.

    SCHEDULE 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    8/14/25 9:25:43 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by ZyVersa Therapeutics Inc.

    10-Q - ZyVersa Therapeutics, Inc. (0001859007) (Filer)

    8/13/25 8:55:58 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Commercial Officer Cashmere Karen A.

    4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

    7/16/25 12:55:04 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Finizio Robert G

    4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

    7/15/25 4:22:54 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Glover Stephen C.

    4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)

    7/15/25 4:22:55 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVSA
    Financials

    Live finance-specific insights

    View All

    ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones

    KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with interim results expected ~Q4-2025. IND-enabling obesity preclinical study with Inflammasome ASC Inhibitor IC 100 in a diet-induced obesity (DIO) animal model planned to begin ~Q4-2025. Invited MJFF grant request submitted for funding Parkinson's disease animal model proof-of-concept studies; response expected Q3-2025. Raised approximately $2.05 million since the end of Q2-2025; $4.05 million year-to-date. WESTON, Fla., Aug. 13, 2025 (GLOBE NEWSWIR

    8/13/25 9:00:00 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress

    KEY HIGHLIGHTS First patient expected to start therapy by end of Q2-2025 in Phase 2a proof-of concept clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease (DKD).Obesity-associated cardiometabolic preclinical proof-of-concept study with Inflammasome ASC Inhibitor IC 100 planned to begin by end of Q2-2025.Investigational New Drug Application (IND) for IC 100 anticipated to be submitted H2-2025, followed by initiation of a Phase 1 clinical trial in healthy overweight subjects at risk of cardiometabolic diseases.Groundbreaking data demonstrating IC 100 blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation — bot

    5/12/25 4:35:00 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

    KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR 200's lead indication, focal segmental glomerulosclerosis (FSGS), expected to be shorter based on FDA's alignment with data supporting proteinuria reduction as a clinical trial endpoint for approval of FSGS drugs (Parasol Initiative). Obesity proof-of-concept studies with Inflammasome ASC Inhibitor IC 100 in diet-induced obesity (DIO) mouse models are planned to begin H1-2025.Investigational New Drug Application (IND) for IC 100 is anticipated to be submitted H2-2025, followed by initiation

    3/27/25 9:15:00 AM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ZVSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ZyVersa Therapeutics Inc.

    SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)

    11/14/24 6:01:27 PM ET
    $ZVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care